Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Occurrence of BRAF and RET mutation in thyroid patients (CROSBI ID 600705)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Gerić, Marko ; Janušić, Renato ; Šarčević, Božena ; Garaj-Vrhovac, Vera Occurrence of BRAF and RET mutation in thyroid patients // Periodicum biologorum. 2012. str. 51-51

Podaci o odgovornosti

Gerić, Marko ; Janušić, Renato ; Šarčević, Božena ; Garaj-Vrhovac, Vera

engleski

Occurrence of BRAF and RET mutation in thyroid patients

Although endocrine cancer in Croatian population represents 2.51% of all cancers, in the few recent years constant increase of incidence was observed. Among cancers of endocrine system, the cancer of thyroid gland is the most frequent. In present study, the aim was to investigate occurrence of BRAF and RET mutations in patients suffering from thyroid illness. The 20 patients were divided into three groups: (1) Papillary thyroid cancer (PTC), (2) Follicular thyroid adenoma (FTA), and (3) other thyroid diseases (Hashimoto, thyreoiditis) patients. Mean age for PTC group was 48.8 years, consisted of 5 volunteers. FTA group mean age was 50.5 years and consisted of 10 volunteers, while the last group mean age was 51.4 years and consisted of 5 volunteers. After analysis of antibody labeled tissue, results showed that all patients had increased levels of either BRAF or RET proteins. PTC patients had 2 positive BRAF and 2 positive RET mutations, while one patient had positive results for both proteins tested. FTA patients, on the other hand, had 2 positive BRAF and 8 positive RET mutations, while patients with other diseases similarly had 4 positive RET and 1 positive both RET and BRAF mutation. Taken together most patients have only one mutated upstream protein which can then activate one of the downstream MAPK pathways. There is possibility that BRAF is under direct control of RET receptor and that is why there is not so many both RET and BRAF mutations.

Papillary thyroid cancer; Follicular thyroid adenoma; BRAF; RET

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

51-51.

2012.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Periodicum biologorum

0031-5362

Podaci o skupu

Second Meeting of the Croatian Association for Cancer Research with International Participation

poster

08.11.2012-09.11.2012

Zagreb, Hrvatska

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti, Biologija

Indeksiranost